These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37379656)

  • 1. Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice.
    Ying Z; van Eenige R; Ge X; van Marwijk C; Lambooij JM; Guigas B; Giera M; de Boer JF; Coskun T; Qu H; Wang Y; Boon MR; Rensen PCN; Kooijman S
    EBioMedicine; 2023 Jul; 93():104684. PubMed ID: 37379656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice.
    van Eenige R; Ying Z; Tramper N; Wiebing V; Siraj Z; de Boer JF; Lambooij JM; Guigas B; Qu H; Coskun T; Boon MR; Rensen PCN; Kooijman S
    Atherosclerosis; 2023 May; 372():19-31. PubMed ID: 37015151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice.
    van Eenige R; Ying Z; Tambyrajah L; Pronk ACM; Blomberg N; Giera M; Wang Y; Coskun T; van der Stelt M; Rensen PCN; Kooijman S
    J Lipid Res; 2021; 62():100070. PubMed ID: 33766515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1.
    Hammoud R; Drucker DJ
    Nat Rev Endocrinol; 2023 Apr; 19(4):201-216. PubMed ID: 36509857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary choline increases brown adipose tissue activation markers and improves cholesterol metabolism in female APOE*3-Leiden.CETP mice.
    Liu C; Song Z; Li Z; Boon MR; Schönke M; Rensen PCN; Wang Y
    Int J Obes (Lond); 2023 Mar; 47(3):236-243. PubMed ID: 36732416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
    Thondam SK; Cuthbertson DJ; Wilding JPH
    Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice.
    Parlevliet ET; Wang Y; Geerling JJ; Schröder-Van der Elst JP; Picha K; O'Neil K; Stojanovic-Susulic V; Ort T; Havekes LM; Romijn JA; Pijl H; Rensen PC
    PLoS One; 2012; 7(11):e49152. PubMed ID: 23133675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
    Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
    Elife; 2023 Jan; 12():. PubMed ID: 36648330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
    Regmi A; Aihara E; Christe ME; Varga G; Beyer TP; Ruan X; Beebe E; O'Farrell LS; Bellinger MA; Austin AK; Lin Y; Hu H; Konkol DL; Wojnicki S; Holland AK; Friedrich JL; Brown RA; Estelle AS; Badger HS; Gaidosh GS; Kooijman S; Rensen PCN; Coskun T; Thomas MK; Roell W
    Cell Metab; 2024 Jul; 36(7):1534-1549.e7. PubMed ID: 38878772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus.
    Smith C; Patterson-Cross R; Woodward O; Lewis J; Chiarugi D; Merkle F; Gribble F; Reimann F; Adriaenssens A
    Appetite; 2022 Jul; 174():106022. PubMed ID: 35430298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
    Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
    J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.
    West JA; Tsakmaki A; Ghosh SS; Parkes DG; Grønlund RV; Pedersen PJ; Maggs D; Rajagopalan H; Bewick GA
    PLoS One; 2021; 16(3):e0249239. PubMed ID: 33788878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122.
    Chai C; Cox B; Yaish D; Gross D; Rosenberg N; Amblard F; Shemuelian Z; Gefen M; Korach A; Tirosh O; Lanton T; Link H; Tam J; Permyakova A; Ozhan G; Citrin J; Liao H; Tannous M; Hahn M; Axelrod J; Arretxe E; Alonso C; Martinez-Arranz I; Betés PO; Safadi R; Salhab A; Amer J; Tber Z; Mengshetti S; Giladi H; Schinazi RF; Galun E
    Gastroenterology; 2020 Sep; 159(3):999-1014.e9. PubMed ID: 32450149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
    McGlone ER; Hope DCD; Davies I; Dore M; Goldin R; Jones B; Liu Z; Li JV; Vorkas PA; Khoo B; Carling D; Minnion J; Bloom SR; Tan TM
    Biomed Pharmacother; 2024 Jul; 176():116888. PubMed ID: 38861859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of DHCR24 activates LXRα to ameliorate hepatic steatosis and inflammation.
    Zhou E; Ge X; Nakashima H; Li R; van der Zande HJP; Liu C; Li Z; Müller C; Bracher F; Mohammed Y; de Boer JF; Kuipers F; Guigas B; Glass CK; Rensen PCN; Giera M; Wang Y
    EMBO Mol Med; 2023 Aug; 15(8):e16845. PubMed ID: 37357756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-tissue omics analysis discovers ten adipose genes encoding secreted proteins in obesity-related non-alcoholic fatty liver disease.
    Darci-Maher N; Alvarez M; Arasu UT; Selvarajan I; Lee SHT; Pan DZ; Miao Z; Das SS; Kaminska D; Örd T; Benhammou JN; Wabitsch M; Pisegna JR; Männistö V; Pietiläinen KH; Laakso M; Sinsheimer JS; Kaikkonen MU; Pihlajamäki J; Pajukanta P
    EBioMedicine; 2023 Jun; 92():104620. PubMed ID: 37224770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.